(CercleFinance.com) – Bristol Myers Squibb announces that it has received a favorable opinion from the CHMP for Reblozyl (luspatercept) in the treatment of adults with transfusion anemia due to low to intermediate risk myelodysplastic syndromes (MDS).
The recommendation of the Committee for Medicinal Products for Human Use (CHMP) will now be examined by the European Commission. If approved, this would be the fourth authorized indication for Reblozyl in the European Union.
‘In the pivotal phase III COMMANDS study, Reblozyl almost doubled the percentage of patients achieving both transfusion independence and increased hemoglobin compared to epoetin alfa’, underlines the health group.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
